Heart enlargement (Cardiomegaly)

Heart enlargement, or cardiomegaly, refers to increased heart size, typically identified through imaging methods such as chest X-ray, MRI, or echocardiography. Cardiomegaly often results from an overload on the heart's muscle fibres due to conditions like high blood pressure or heart valve disease, leading to structural remodelling of the heart chambers.¹ In the context of heart failure, cardiomegaly commonly occurs as the heart’s ventricles dilate to accommodate increased blood volume, resulting in a weakened ability to pump blood efficiently.²

Heart failure (HF) is a progressive condition where the heart cannot meet the body's metabolic demands, resulting in symptoms like shortness of breath, fatigue, and fluid retention.³ The enlargement of the heart, particularly in the left ventricle, is often a compensatory response to chronic pressure or volume overload. However, this enlargement exacerbates the heart's inefficiency over time, contributing to further functional decline and increasing the likelihood of adverse events such as arrhythmias and hospitalisations.⁴

Heart failure affects over 64 million people worldwide, making it a leading cause of morbidity and mortality globally.⁵ In the United States alone, around 6.2 million adults live with heart failure, and the condition contributes to over 1 million hospitalizations annually.⁶ Mortality rates remain high; within five years of diagnosis, approximately 50% of patients with heart failure will succumb to the disease, reflecting the need for more effective therapies.⁷

Importance of research and innovative treatments

Despite advances in pharmacological and device-based therapies, heart failure with cardiomegaly remains a clinical challenge with high rates of hospital readmissions and mortality.⁸ Research into novel treatments, such as gene therapy, regenerative medicine, and innovative drug therapies, is critical to improving outcomes for patients. These therapies hold promise for enhancing heart function, reducing heart size, and potentially reversing heart failure progression, offering new hope for improved quality of life and survival rates in affected populations.⁸

Types of heart enlargement in heart failure

Systolic vs. Diastolic heart failure

Heart failure can generally be classified as either systolic or diastolic, each affecting heart structure and function differently.

• Systolic Heart Failure: Often termed “heart failure with reduced ejection fraction” (HFrEF), this type occurs when the heart's left ventricle loses its ability to contract effectively, reducing the volume of blood pumped out with each heartbeat.⁸ In response, the heart can enlarge as it attempts to compensate by stretching and dilating to maintain cardiac output, which ultimately contributes to cardiomegaly⁸
• Diastolic Heart Failure: Also known as “heart failure with preserved ejection fraction” (HFpEF), diastolic heart failure arises when the heart muscle becomes stiff and is unable to relax adequately during the filling phase, leading to increased pressure within the heart chambers.⁸ This stiffness can also lead to structural changes and enlargement of the left atrium, although left ventricular enlargement is less prominent in HFpEF than in HFrEF⁸

Common causes of heart enlargement

Heart enlargement in heart failure is often triggered by underlying conditions that place excess strain on the heart:

• High blood pressure (Hypertension): Chronic high blood pressure forces the heart to work harder to pump blood, often resulting in thickening of the heart muscle and subsequent enlargement, especially in the left ventricle⁹
• Valve disease: Malfunctioning heart valves (e.g., mitral or aortic regurgitation) can cause blood to flow backwards or increase the heart's workload, leading to dilation and remodelling of affected chambers⁹
• Cardiomyopathy: This group of diseases directly affects heart muscle function and structure, leading to dilation of the heart chambers in dilated cardiomyopathy, or thickening in hypertrophic cardiomyopathy. These changes are frequently associated with an increased risk of heart failure⁹

Current standard treatments for heart failure with cardiomegaly

Medication

Medications form the foundation of heart failure management:

• Beta-Blockers: These drugs reduce heart rate and lower blood pressure, decreasing the workload on the heart. Beta-blockers have been shown to improve survival and reduce the risk of hospitalization in patients with heart failure⁴
• ACE Inhibitors and Angiotensin Receptor Blockers (ARBs): ACE inhibitors (e.g., enalapril) and ARBs (e.g., losartan) block the effects of angiotensin, a hormone that constricts blood vessels, thereby reducing blood pressure and helping to prevent further heart enlargement⁴

Lifestyle modifications

Lifestyle changes are essential to managing heart failure and preventing further heart enlargement:

• Diet: A heart-healthy diet, low in sodium, helps prevent fluid buildup and reduces blood pressure, which can alleviate strain on the heart¹⁰
• Exercise: Regular, moderate exercise improves cardiovascular fitness and can help reduce symptoms and improve quality of life in heart failure patients¹⁰

Surgical interventions

For advanced heart failure, surgical options may be necessary:

• Left Ventricular Assist Devices (LVADs): These are mechanical pumps implanted to assist the left ventricle in pumping blood. LVADs can be used as a bridge to transplant or as a long-term therapy for those ineligible for a transplant¹¹
• Heart Transplant: In end-stage heart failure, a heart transplant may be the only viable option, offering a significant improvement in survival and quality of life for selected patients¹²
• Valve Surgery: For patients with valve disease, surgical repair or replacement can relieve pressure on the heart and prevent further enlargement¹³

Latest clinical trials and their innovative approaches

Novel pharmacological treatments

Examples of New Drugs in Phase II or III Trials: Emerging drugs focus novel mechanisms and improved efficacy for heart failure patients.

• For example, Omecamtiv Mecarbil is a cardiac myosin activator currently in Phase III trials, designed to enhance contractility in heart failure patients with reduced ejection fraction (HFrEF), showing improvements in cardiac function without increasing oxygen demandMechanisms Targeting Cellular Pathways or Reducing Fibrosis**: New drugs are targeting cellular pathways to mitigate fibrosis, a hallmark of heart enlargement¹⁴
• Angiotensin Receptor-Neprilysin Inhibitors (ARNIs), such as sacubitril/valsartan, are aimed at reducing inflammation and fibrosis by acting on pathways associated with adverse cardiac remodelling, proven to improve outcomes in patients with HFrEF¹⁴

Stem cell therapies

• Gene Editing Trials: Several clinical trials are testing gene therapies like those using adeno-associated virus (AAV) vectors to deliver therapeutic genes directly into the myocardium.
• SERCA2a Gene Therapy uses AAV to improve calcium cycling in cardiac cells, which may reduce heart enlargement and improve contractility.
• SCs) have shoStem Celns: Stem cell therapies are being tested for their regenerative potential.
• Mesenchymal Stem Cells (MSCs) and Induced Pluripotent Stem Cells (iPwn promise to regenerate damaged heart tissue and are currently undergoing Phase II trials for their effects on improving heart function and reducing cardiomegaly⁴

Implantable devichanical supports

• Advancements in LVADs: Left Ventricular Assist Devices (LVADs) have become more advanced, with models like HeartMate 3 demonstrating reduced rates of complications like thrombosis and infections¹⁵
• Non-Invasive Devices or Wehnology: Non-invasive devices, such as the CardioMEMS HF System, enable continuous monitoring of heart failure patients by tracking pulmonary artery pressure, allowing for personalised and real-time management⁴

Bioengineering approaches

• als and Bioengineered Tissue Patches*: Bioengineering techniques are advancing the development of biomaterials that support heart regeneration.
  • Extracellular Matrix Patches derived from decellularized heart tissue have shown early success in animal models and are now being trialed in humans to strengthen damaged heart walls and promote tissue regeneration²

Targeted molecular and immunotherapies

Antibodies and Small Molecules: Monoclonal antibodies like IL-1 blockers are undergoing trials to address the inflammatory processes that contribute to heart failure and cardiomegaly .

• Immunotherapy Targeting Heart-Specific Markers: CARerapies, typically used in cancer, are being adapted to target fibrotic cells in the heart, with early-stage trials exploring their safety and efficacy¹²

Selected noteworthy trials and their results

Three to five major trials

• EMPEROR-Reduced (Phase III): A trial of Empagliflozin (SGLT2 inhibitor) involving multiple institutions demonstrated significant reductions in heart failure hospitalisations and improvement in heart function for patients with HFrEF
• GALACTIC-HF (Phase III): The Omecamtiv Mecarbil trial, supported focuses on enhancing contractile force and showed an improvement in patients’ cardiac output, albeit with mixed outcomes on overall survival
• BEAT-HF (Phase II): In North American sites, the BEAT-HF trial involves mesem cell injections in heart failure patients, showing promising results in heart structure improvements¹⁰

Clinical relevance and potential impact

• The results from these trials indicate that these therapies shift from experimental to standard options, particularly for patients with advanced heart failure who may not respond to conventional treatments¹⁴

Summary

Recent clinical trials reveal significant strides in addressing heart failure and cardiomegaly through innovative treatments. Novel pharmacological agents, such as Omecamtiv Mecarbil and SGLT2 inhibitors, show the potential to improve heart function and patient quality of life by targeting mechanisms directly related to heart muscle performance and fibrosis reduction. Gene and stem cell therapies, including SERCA2a gene editing and mesenchymal stem cell injections, offer groundbreaking regenerative approaches that could reverse heart damage rather than merely slow disease progression. Furthermore, advancements in implantable devices like HeartMate 3 and wearable technologies such as the CardioMEMS HF System have enhanced heart failure management, with bioengineered patches and immunotherapies offering potential additional tools to repair and stabilize the heart muscle.

Importance of continued research and innovation

Continued research and innovation in cardiomegaly and heart failure treatments remain essential to overcoming challenges in patient outcomes and quality of life. Trials must address the limitations in recruitment, cost, safety, and long-term efficacy to ensure these therapies are accessible and viable for all heart failure patients. Ongoing support from the scientific community and healthcare stakeholders is crucial to drive these promising therapies from trials to standard care.

The future of heart failure treatment, particularly for cardiomegaly, appears promising as these cutting-edge therapies evolve. As research progresses, the likelihood of transforming heart failure from a debilitating, life-threatening condition to a manageable disease grows, offering hope for improved survival rates and a better quality of life for millions of patients worldwide. With these innovations, the field stands on the cusp of a new era in cardiovascular medicine, where personalized, regenerative, and precise therapies could reshape the landscape of heart failure management.